Madison Keys, who captured her first Grand Slam title last month in Melbourne, has not played since her title-run Down Under.

Raymond James lowered the firm’s price target on Hologic (HOLX) to $90 from $95 and keeps an Outperform rating on the shares. Hologic’s print ...

Essex Mitchell; Chief Operating Officer; Hologic Inc Karleen Oberton; Chief Financial Officer; Hologic Inc Tycho Peterson; Analyst; Jeffries. Tejas Savant; Analyst; Morgan Stanley & Co. LLC Andrew ...

Hologic, Inc. HOLX reported adjusted earnings per share (EPS) of $1.03 in the first quarter of fiscal 2025, up 5.1% year over year. The metric surpassed the Zacks Consensus Estimate by 0.9%. Find the ...

Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

The stock's rise snapped a three-day losing streak.

Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the ...

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...